Graduate School of Pharmacy and Pharmaceutical Sciences, Josai University.
Department of Pharmacy, University of San Carlos.
Chem Pharm Bull (Tokyo). 2020;68(8):779-783. doi: 10.1248/cpb.c20-00289.
Tranilast, a lipophilic drug with various ophthalmic applications, was used as a model drug to establish the possibility of delivering lipophilic drugs through the eyelid skin. Pharmacokinetics and tissue distribution studies were conducted employing three application methods (topical application onto eyelid skin, eye drops, and intravenous injection in rats) to broaden the significance of delivering drugs through the eyelids. A two-compartment open model analysis was used for intravenous route while a non-compartmental evaluation was used for topical applications to estimate the pharmacokinetic parameters. Eyelid skin application, eye drops, and intravenous administration had mean residence times (MRTs) of 8.07, 1.79, and 3.25 h in the eyeball and 10.8, 1.29, and 2.97 h in the conjunctiva, correspondingly. In the eyeball, topical application of tranilast onto the eyelids corresponded to a 4.5- and 2.5-fold higher MRT compared with eye drops and intravenous administration, respectively. An 8.4- or 3.6-fold higher MRT was observed in the conjunctiva after topical application compared with eye drops or intravenous administration, respectively. This indicated a gradual penetration of tranilast into the eyeball and conjunctiva, subsequently a slow elimination from these target tissues.
曲尼司特是一种具有多种眼科应用的亲脂性药物,被用作模型药物,以验证通过眼睑皮肤递送亲脂性药物的可能性。采用三种应用方法(局部应用于眼睑皮肤、滴眼剂和静脉注射)进行药代动力学和组织分布研究,以拓宽通过眼睑递药的意义。静脉途径采用双室开放模型分析,局部应用采用非房室评价来估计药代动力学参数。在眼球中,眼睑皮肤应用、滴眼剂和静脉给药的平均驻留时间(MRT)分别为 8.07、1.79 和 3.25 h,在结膜中分别为 10.8、1.29 和 2.97 h。在眼球中,与滴眼剂和静脉给药相比,曲尼司特局部应用于眼睑的 MRT 分别高出 4.5 倍和 2.5 倍。与滴眼剂或静脉给药相比,结膜局部应用的 MRT 分别高出 8.4 倍或 3.6 倍。这表明曲尼司特逐渐渗透到眼球和结膜中,随后从这些靶组织中缓慢消除。